These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36916768)

  • 1. Rhabdomyosarcoma with isolated lung metastases: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Vasquez JC; Luo LY; Hiniker SM; Rhee DS; Dasgupta R; Chen S; Weigel BJ; Xue W; Venkatramani R; Arndt CA
    Pediatr Blood Cancer; 2023 Jun; 70(6):e30293. PubMed ID: 36916768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adolescents and young adults with rhabdomyosarcoma: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Harrison DJ; Qumseya A; Xue W; Arnold M; Lautz TB; Hiniker SM; Thomas SM; Venkatramani R; Weiss AR; Mascarenhas L
    Pediatr Blood Cancer; 2024 Apr; 71(4):e30847. PubMed ID: 38282125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics and outcomes of rhabdomyosarcoma patients with isolated lung metastases from IRS-IV.
    Rodeberg D; Arndt C; Breneman J; Lyden E; Donaldson S; Paidas C; Andrassy R; Meyer W; Wiener E
    J Pediatr Surg; 2005 Jan; 40(1):256-62. PubMed ID: 15868594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical and prognostic analysis of single-center multidisciplinary treatment for rhabdomyosarcoma in children].
    Xu N; Duan C; Jin M; Zhang DW; Su Y; Yu T; He LJ; Fu LB; Zeng Q; Wang HM; Zhang WP; Ni X; Ma XL
    Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):767-773. PubMed ID: 31594063
    [No Abstract]   [Full Text] [Related]  

  • 5. Histologic and clinical characteristics can guide staging evaluations for children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee.
    Weiss AR; Lyden ER; Anderson JR; Hawkins DS; Spunt SL; Walterhouse DO; Wolden SL; Parham DM; Rodeberg DA; Kao SC; Womer RB
    J Clin Oncol; 2013 Sep; 31(26):3226-32. PubMed ID: 23940218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of outcomes based on treatment algorithms for rhabdomyosarcoma of the bladder/prostate: combined results from the Children's Oncology Group, German Cooperative Soft Tissue Sarcoma Study, Italian Cooperative Group, and International Society of Pediatric Oncology Malignant Mesenchymal Tumors Committee.
    Rodeberg DA; Anderson JR; Arndt CA; Ferrer FA; Raney RB; Jenney ME; Brecht IB; Koscielniak E; Carli M; Bisogno G; Oberlin O; Rey A; Ullrich F; Stevens MC; Meyer WH
    Int J Cancer; 2011 Mar; 128(5):1232-9. PubMed ID: 20473932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group.
    Hibbitts E; Chi YY; Hawkins DS; Barr FG; Bradley JA; Dasgupta R; Meyer WH; Rodeberg DA; Rudzinski ER; Spunt SL; Skapek SX; Wolden SL; Arndt CAS
    Cancer Med; 2019 Oct; 8(14):6437-6448. PubMed ID: 31456361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group.
    Meza JL; Anderson J; Pappo AS; Meyer WH;
    J Clin Oncol; 2006 Aug; 24(24):3844-51. PubMed ID: 16921036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children's Oncology Group.
    Rodeberg DA; Garcia-Henriquez N; Lyden ER; Davicioni E; Parham DM; Skapek SX; Hayes-Jordan AA; Donaldson SS; Brown KL; Triche TJ; Meyer WH; Hawkins DS
    J Clin Oncol; 2011 Apr; 29(10):1304-11. PubMed ID: 21357792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management and outcomes of chest wall rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee.
    Lautz TB; Xue W; Luo LY; Fair D; Qumseya A; Gao Z; Dasgupta R; Rodeberg D; Venkatramani R
    Pediatr Blood Cancer; 2023 Jul; 70(7):e30357. PubMed ID: 37070563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy and prognostic significance of regional lymph node involvement in embryonal rhabdomyosarcoma: a report from the European paediatric Soft tissue sarcoma Study Group.
    Ben-Arush M; Minard-Colin V; Scarzello G; Fajardo RD; Terwisscha Van Scheltinga S; Bernier V; Jenney M; Gallego S; Zanetti I; Cesen M; Merks JHM; Bisogno G
    Eur J Cancer; 2022 Sep; 172():119-129. PubMed ID: 35763871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of chemotherapy-induced toxicities and outcome in children and adolescents with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.
    Gupta AA; Chi YY; Anderson JR; Lyden E; Weigel B; Arndt C; Meyer WH; Rosenberg A; Hawkins DS
    Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28333415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results in patients with cranial parameningeal sarcoma and metastases (Stage 4) treated on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols II-IV, 1978-1997: report from the Children's Oncology Group.
    Raney B; Anderson J; Breneman J; Donaldson SS; Huh W; Maurer H; Michalski J; Qualman S; Ullrich F; Wharam M; Meyer W;
    Pediatr Blood Cancer; 2008 Jul; 51(1):17-22. PubMed ID: 18266224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.
    Rudzinski ER; Anderson JR; Chi YY; Gastier-Foster JM; Astbury C; Barr FG; Skapek SX; Hawkins DS; Weigel BJ; Pappo A; Meyer WH; Arnold MA; Teot LA; Parham DM
    Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28521080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of fusion status, Oberlin risk factors, local and maintenance treatment in pediatric and adolescent patients with metastatic rhabdomyosarcoma: Data of the European Soft Tissue Sarcoma Registry SoTiSaR.
    Heinz AT; Schönstein A; Ebinger M; Fuchs J; Timmermann B; Seitz G; Vokuhl C; Münter M; Pajtler KW; Stegmaier S; von Kalle T; Kratz CP; Ljungman G; Juntti H; Klingebiel T; Koscielniak E; Sparber-Sauer M;
    Pediatr Blood Cancer; 2024 Jan; 71(1):e30707. PubMed ID: 37814424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival outcomes of patients with localized FOXO1 fusion-positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Heske CM; Chi YY; Venkatramani R; Li M; Arnold MA; Dasgupta R; Hiniker SM; Hawkins DS; Mascarenhas L
    Cancer; 2021 Mar; 127(6):946-956. PubMed ID: 33216382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors.
    Carli M; Colombatti R; Oberlin O; Bisogno G; Treuner J; Koscielniak E; Tridello G; Garaventa A; Pinkerton R; Stevens M
    J Clin Oncol; 2004 Dec; 22(23):4787-94. PubMed ID: 15570080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report.
    Skapek SX; Anderson J; Barr FG; Bridge JA; Gastier-Foster JM; Parham DM; Rudzinski ER; Triche T; Hawkins DS
    Pediatr Blood Cancer; 2013 Sep; 60(9):1411-7. PubMed ID: 23526739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival of patients with orbital and eyelid rhabdomyosarcoma treated on Children's Oncology Group studies from 1997 to 2013: A report from the Children's Oncology Group.
    Metts J; Xue W; Gao Z; Ermoian R; Bradley JA; Arnold MA; Dasgupta R; Venkatramani R; Walterhouse D
    Cancer; 2023 Jun; 129(11):1735-1743. PubMed ID: 36857314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
    Hawkins DS; Chi YY; Anderson JR; Tian J; Arndt CAS; Bomgaars L; Donaldson SS; Hayes-Jordan A; Mascarenhas L; McCarville MB; McCune JS; McCowage G; Million L; Morris CD; Parham DM; Rodeberg DA; Rudzinski ER; Shnorhavorian M; Spunt SL; Skapek SX; Teot LA; Wolden S; Yock TI; Meyer WH
    J Clin Oncol; 2018 Sep; 36(27):2770-2777. PubMed ID: 30091945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.